Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

ABSTRACT

Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.

RELATED APPLICATIONS

This patent application is a continuation of U.S. application Ser. No.13/333,497, filed Dec. 21, 2011, which is a divisional of U.S.application Ser. No. 11/749,728, filed May 16, 2007, which claimspriority of Provisional Patent Application Ser. No. 60/747,313, filedMay 16, 2006 and entitled “Galactose-Pronged Polysaccharides in aFormulation for Antifibrotic Therapies.” Each of the aforementionedapplications is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

Fibrosis is an intermediate result of and a pathological process itselfleading from tissue injury through its encapsulation by extracellularmatrix to a pathological formation of scar tissue.

Injury leading to fibrosis occurs in response to a variety of chronicinsults including alcohol abuse, drugs, toxins, viral hepatitis B and C,some metabolic diseases, foreign objects, such as small mineral ororganic particles (e.g., in the lungs), causing chronic and/or permanenttissue irritation, or other hepatic or pulmonary abnormalities. Theadvanced stage of fibrosis is cirrhosis, defined by the presence ofencapsulated nodules, and eventually cancer.

Fibrosis is a systemic response to chronic injury, developing through aseries of highly coordinated molecular events, collectively calledfibrogenesis. In one example, fibrosis develops as a result of chronicmammalian liver injury. The steps immediately following chronicmammalian liver injury represent a process called “initiation”, which inturns are early events of “activation” of hepatic stellate cells. Thenext step of stellate cells activation is “perpetuation”, and this leadsto proliferation, fibrogenesis and matrix degradation. Each of theseevents is accompanied by specific molecular markers, such as collagen I(a marker on fibrosis), alpha 1-smooth muscle actin (a marker onactivation of stellate cells), beta PDGF-receptor (a marker onproliferation), matrix metalloproteinases and their inhibitors MMP2,MMP9, TIMP1 and TMP2 (markers on matrix degradation), cytokine TFG-β1 (amarker on fibrogenesis).

Development of fibrosis can be evaluated by the quantitative level ofthe respective markers. Reduction of fibrosis can be evaluated by thedecrease of the level of the respective markers during various stages offibrosis. Fibrosis can be reduced and reversed. Furthermore, even theadvanced stage of fibrosis, cirrhosis, can also be reversed.

SUMMARY OF THE INVENTION

In one embodiment, methods and compositions are provided that relate tothe administration of a galactopolysaccharide in a combination with aantifibrotic compound to a subject in a formulation in which fibrosis isreduced.

In another embodiment, a method is provided for treating fibrosis in asubject, by administering an effective dose of a antifibrotic compoundto the subject in a formulation containing a suitable polysaccharide,which may include, but is not limited to, a galactomannan,rhamnogalacturonan, arabinogalactan, combining the polysaccharide withthe effective dose of a suitable compound to form a mixture; andadministering the mixture to the subject.

In another embodiment, the present invention relates to a method fordelivering an effective dose of an admixture of a suitablegalactose-containing polysaccharide and a compound selected from thegroup consisting of antibodies specific to cell-surface and/orintracellular: (i) β-PDGF receptors; (ii) synaptophysin; (iii) zvegf3;(iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9;(viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix)integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii)collagen synthesis and degradation modulating compounds; (xiii) actinsynthesis and degradation modulating compounds; and (xiv) tyrosinekinases.

In another embodiment, the present invention relates to a method fordelivering an effective dose of an admixture of a suitablegalactose-containing polysaccharide and a compound selected from thegroup consisting of: (i) IL-1; (ii) IL-10; (iii) anti-zvegf3 compounds;(iv) interferon alpha G (alpha 5); and (v) hepatic stellate cellactivation inhibiting compounds.

In another embodiment, the present invention relates to a method fordelivering an effective dose of an admixture of a suitablegalactose-containing polysaccharide and a compound selected from thegroup consisting of: (i) Vitamin E; (ii) alpha-lipoic acid; (iii)Tetrandrine; (iv) Silymarin and Silymarin derivatives; and (v)Thalidomide and Thalidomide analogs.

In another embodiment, the present invention relates to a method fordelivering an effective dose of an admixture of a suitablegalactose-containing polysaccharide and a compound selected from thegroup consisting of: (i) cysteine; (ii) L-cysteine; (iii) L-methionine;(iv) S-adenosyl methionine; (v) S-methyl cysteine; and (vi) N-acetylcysteine.

In another embodiment, the present invention relates to a method fordelivering an effective dose of an admixture of a suitablegalactose-containing polysaccharide and a compound selected from thegroup consisting of: (i) copper chelating compounds; (ii) halofuginone;(iii) β-amino-propionitriles; (iv) Type V cyclic nucleotidephosphodiesterase inhibitors; (v) antiviral compounds; (vi) alcoholabstinence compounds; and (vii) herbal compounds.

In another embodiment, the present invention relates to a method fordelivering an effective dose of an admixture of a suitablegalactose-containing polysaccharide and a compound selected from thegroup consisting of: (i) dextran sulfate; (ii) pentosan polysulfate;(iii) chondroitin sulfate; (iv) heparin sulfate; and (v) heparin.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the scission of polysaccharides by ascorbate and/orperoxide (H₂O₂). The effect of 10 mM H₂O₂ (□), 10 mM ascorbate (∘) or 5mM of each (Δ) is shown.

FIG. 2 shows the effect of galacto-polysaccharides' derivatives onmolecular markers of fibrogenesis.

FIG. 3 shows the cell viability, treatments versus control untreated.

FIG. 4 shows the proliferation results of 3 galacto-polysaccharides onhepatic stellate cell (LX2 Cell line) using ³H-thymidine incorporationassay.

DETAILED DESCRIPTION OF THE INVENTION

Detailed embodiments of the present invention are disclosed herein;however, it is to be understood that the disclosed embodiments aremerely illustrative of the invention that may be embodied in variousforms. In addition, each of the examples given in connection with thevarious embodiments of the invention are intended to be illustrative,and are not restrictive. Therefore, specific structural and functionaldetails disclosed herein are not to be interpreted as limiting, butmerely as a representative basis for teaching one skilled in the art tovariously employ the present invention.

The following terms shall have the meanings indicated herein and in theclaims, unless required otherwise by the context.

“PS” shall mean polysaccharide.

“EHS” shall mean Eaglebreth-Holm Swarm.

“DMEM” shall mean Dulbecco's Soluble branched Eagle's Minimal EssentialMedium.

“CMF-PBS” shall mean Ca²⁺- and Mg²⁺-Free Phosphate-Buffered Saline, pH7.2.

“BSA” shall mean Bovine Serum Albumin.

“galUA” shall mean galactopyranosyl uronic acid, also calledgalacturonic acid.

“gal” shall mean galactose.

“man” shall mean mannose.

“glc” shall mean glucose.

“all” shall mean allose.

“alt” shall mean altrose.

“ido” shall mean idose.

“tal” shall mean talose.

“gul” shall mean gulose.

“ara” shall mean arabinose.

“rib” shall mean ribose.

“lyx” shall mean lyxose.

“xyl” shall mean xylose.

“fru” shall mean fructose.

“psi” shall mean psicose.

“sor” shall mean sorbose.

“tag” shall mean tagatose.

“rha” shall mean rhamnose.

“fuc” shall mean fucose.

“quin” shall mean quinovose.

“2-d-rib” shall mean 2-deoxy-ribose.

“Administration” refers to oral, or parentereal including intravenous,subcutaneous, topical, transdermal, intradermal, transmucosal,intraperitoneal, intramuscular, intracapsular, intraorbital,intracardiac, transtracheal, subcutaneous, subcuticular, intraarticular,subcapsular, subarachnoid, intraspinal, epidural and intrasternalinjection and infusion.

“Subject” is defined here and in the claims as a mammal including ahuman in need of therapy for, or susceptible to, a condition or itssequelae. The subject may include dogs, cats, pigs, cows, sheep, goats,horses, rats, and mice and humans. The term “subject” does not excludean individual that is normal in all respects.

“Patient” shall mean a human subject who has presented at a clinicalsetting with a particular symptom or symptoms suggesting the need fortreatment.

“Treatment of fibrosis” refers to prognostic treatment of subjects athigh risk of developing a fibrotic or cirrhotic condition as well assubjects who have already developed a fibrotic or cirrhotic condition,regardless of location or type of tissue in which the fibrotic orcirrhotic condition arises.

“Treatment” may also be applied to the reduction or prevention ofabnormal cell proliferation, cell aggregation and cell dispersal(metastasis).

“Cirrhosis” refers to any tissue disorder, including such cellulardisorders including, but not limited to, renal cirrhosis, livercirrhosis, ovarian cirrhosis, lung cirrhosis, gastrointestinal orstomach cirrhosis. The term “cirrhosis” refers to an advanced stage offibrosis, defined by the presence of encapsulated nodules, andeventually cancer. For purposes of this specification and claims,“cirrhosis” is considered to be a type of fibrosis, and is includedwithin the meaning of the term “fibrosis” used herein.

“Fibrosis” refers to any tissue disorder, including, but not limited to,such cellular disorders as, for example, cirrhosis, Kidney fibrosis,liver fibrosis, ovarian fibrosis, lung fibrosis, gastrointestinal orstomach fibrosis, Fibroids. The term “fibrosis” refers to both thepathological process leading from tissue injury through itsencapsulation by extracellular matrix, and the result of the process,which is a pathological formation of scar tissue. Fibrosis is a systemicresponse to chronic injury, developing through a series of highlycoordinated molecular events, collectively called fibrogenesis. Thesteps immediately following chronic liver injury represent a processcalled “initiation”, which in turns are early events of “activation” ofhepatic stellate cells. The next step of stellate cells activation is“perpetuation”, and this leads to proliferation, fibrogenesis and matrixdegradation.

“Molecular markers”, or “Biochemical markers”, or “Biomarkers”, or“Markers” refers to individual molecules of biological origin, which canbe monitored as a “readout” of specific metabolic events. These eventsare accompanied by formation of the “markers”, the quantitative level ofwhich can often be used as an indication to advancement of the event.Examples of such markers in fibrosis are collagen I (a marker onfibrosis), alpha 1-smooth muscle actin (a marker on activation ofstellate cells), beta PDGF-receptor (a marker on proliferation), matrixmetalloproteinases and their inhibitors MMP2, MMP9, TIMP1 and TMP2(markers on matrix degradation), cytokine TFG-β1 (a marker onfibrogenesis).

“Admixture” means more than one component mixed together to form acombination. For purposes of the present invention, “admixture” meansthe mixture of two or more compounds at any time prior or subsequent to,or concomitant with, administration.

“Depolymerization” refers to partial or complete hydrolysis of thepolysaccharide backbone occurring for example when the polysaccharide istreated chemically resulting in fragments of reduced size when comparedwith the original polysaccharide.

“Effective dose” refers to a dose of a compound and/or admixture thatimproves the symptoms of the subject or the longevity of the subjectsuffering from or at high risk of suffering from cirrhosis. Theeffective dose in embodiments of this invention can be quantitativelydefined as an amount of a polysaccharide compound administered alone orin a mixture with a dose of a antifibrotic compound administered in asubject for treating fibrosis that decreases a level of a chosenmolecular marker by at least about 5 percent.

“Saccharide” refers to any simple carbohydrate includingmonosaccharides, monosaccharide derivatives, monosaccharide analogs,sugars, including those, which form the individual units in anoligosaccharide or a polysaccharide.

“Monosaccharide” refers to polyhydroxyaldehyde (aldose) orpolyhdroxyketone (ketose) and derivatives and analogs thereof.

“Oligosaccharide” refers to a linear or branched chain ofmonosaccharides that includes up to about 10 saccharides units linkedvia glycosidic bonds.

“Polysaccharide” refers to polymers formed from about 10 to over 100,000saccharide units linked to each other by hemiacetal or glycosidic bonds.The polysaccharide may be either a straight chain, singly branched, ormultiply branched wherein each branch may have additional secondarybranches, and the monosaccharides may be standard D- or L-cyclic sugarsin the pyranose (6-membered ring) or furanose (5-membered ring) formssuch as D-fructose and D-galactose, respectively, or they may be cyclicsugar derivatives, for example amino sugars such as D-glucosamine, deoxysugars such as D-fucose or L-rhamnose, sugar phosphates such asD-ribose-5-phosphate, sugar acids such as D-galacturonic acid, ormulti-derivatized sugars such as N-acetyl-D-glucosamine,N-acetylneuraminic acid (sialic acid), or N-sulfato-D-glucosamine. Whenisolated from nature, polysaccharide preparations comprise moleculesthat are heterogeneous in molecular weight. Polysaccharides include,among other compounds, galactomanans and galactomannan derivatives;galacto-rhamnogalacturons and galacto-rhamnogalacturon derivatives, andgalacto-arabinogalacturon and galacto-arabinogalacturon derivatives.

“Backbone” means the major chain of a polysaccharide, or the chainoriginating from the major chain of a starting polysaccharide, havingsaccharide moieties sequentially linked by either α or β glycosidicbonds. A backbone may comprise additional monosaccharide moietiesconnected thereto at various positions along the sequential chain.

“Esterification” refers to the presence of methylesters or other estergroups at the carboxylic acid position of the uronic acid moieties of asaccharide.

“Monosaccharides and their derivatives” refers to, within the context ofthis invention, any of the standard and possible derivatives ofmonosaccharides (sugars), including but not limited todeoxymonosaccharides, dideoxymonosaccharides, sugar alcohols, sugaracids, sugar esters, sugar ethers, sugar halides, amino sugars, sugarphosphates, pyranose and furanose cyclic forms, open ring forms,sulfonic esters of sugars, glycosidic derivatives, glycols, glycolenes,keto sugars, diketo sugars, protected sugars, acetals such asbenzilidenes and ketals such as isopropylidenes, nitro sugars, N-acetylsugars, N-acetylmuramic acid, and antibiotic sugars such as nojirimycinand dihydronojirimycin.

“Efficacy” of a antifibrotic compound refers to the relationship betweena minimum effective dose and an extent of toxic side effects. Efficacyof an compound is increased if a antifibrotic end point can be achievedby administration of a lower dose or a shorter dosage regimen. Iftoxicity can be decreased, a antifibrotic compound can be administeredon a longer dosage regimen or even chronically with greater patientcompliance and improved quality of life. Further, decreased toxicity ofan compound enables the practitioner to increase the dosage to achievethe antifibrotic endpoint sooner, or to achieve a higher antifibroticendpoint.

“Pharmaceutically acceptable carrier” refers to any and all solvents,dispersion media, e.g., human albumin or cross-linked gelatinpolypeptides, coatings, antibacterial and antifungal compounds,isotonic, e.g., sodium chloride or sodium glutamate, and absorptiondelaying compounds, and the like that are physiologically compatible.The use of such media and compounds for pharmaceutically activesubstances is well known in the art. Preferably, the carrier is suitablefor oral, intravenous, intramuscular, subcutaneous, parenteral, spinalor epidural administration (e.g., by injection or infusion). Dependingon the route of administration, the active compound can be coated in amaterial to protect the compound from the action of acids and othernatural conditions that can inactivate the compound.

In one embodiment, the collagen marker is measured and quantitated bymorphometry, using four picrosirius red stained slides per animal. Ninepictures are taken randomly per slide, for a total 36 pictures peranimal, which are then evaluated using the BIOQUANT™ image analysisprogram.

In another embodiment the following markers—alpha 1-smooth muscle actin,beta PDGF-receptor, TGF-beta receptor, MMP1, MMP2, MMP13, TIMP1, TMP2and collagen I—are assessed using cDNA obtained by reverse transcriptionfrom mRNA, extracted from liver tissue.

In one embodiment an effective amount of a polysaccharide compoundadministered alone or in a mixture with a dose of a therapeutic agentadministered in a subject for treating fibrosis is defined as onedecreasing a level of a chosen molecular marker by 20 percent.

In another embodiment the effective amount of an administeredpolysaccharide compound is defined as decreasing a chosen molecularmarker between 5 and 50 percent and higher, depending on an advancementof the disease.

In one embodiment, an effective amount of a polysaccharide compoundadministered alone or in a mixture with a dose of a antifibroticcompound administered in a subject for treating fibrosis is defined asone decreasing a level of a chosen molecular marker by 20 percent.

In yet another embodiment an effective amount of an administeredpolysaccharide compound is defined as decreasing a chosen molecularmarker between 5 and 50 percent and higher, depending on an advancementof the disease.

In another embodiment, if an inducer of fibrosis, such as carbontetrachloride (subcutaneously) or thioacetamide (intra-peritoneally)administered alone, causes formation of the biochemical markers, but aconcurrent administration of the inducer and a suitable polysaccharideincluding but not limited to galactomannan, rhamnogalacturonan, orarabinogalactan, does not lead to formation of the same marker, or leadsto formation of the same marker but in a reduced amount, it can besuggested that said polysaccharide prevents or slows down fibrosis.

In yet another embodiment, if said polysaccharide is administered atlater stages of development of fibrosis, and the administration causesreduction of the level of the biochemical markers compared to that incontrol or to that in the same experimental animal, it can be suggestedthat the polysaccharide is able to reverse or slow down fibrosis.

In yet another embodiment, if said polysaccharide is administered atlater stages of development of fibrosis, and the administration causesreducing of the level of the biochemical markers compared to that incontrol or to that in the same experimental animal, and then subsequentdisappearance of the markers coincides with the return to health of asubject with respect to this particular pathology, it can be suggestedthat the polysaccharide is able to reverse fibrosis.

In yet another embodiment, if said polysaccharide is administered at thelate stages of fibrosis, which can be determined as cirrhosis, and theadministration causes a reduction of the level of the biochemicalmarkers compared to that in control or to that in the same experimentalanimal, it can be suggested that the polysaccharide is able to slow downor reverse cirrhosis.

In yet another embodiment, if said polysaccharide is administered atlater stages of development of fibrosis, and the administration causesreduction of the level of the biochemical markers compared to that incontrol or to that in the same experimental animal by at leastapproximately 5%, it can be suggested that the polysaccharide is able toreverse or slow down fibrosis.

In one embodiment of the patent a method for treating a fibrosis in asubject is disclosed, comprising administering parenterally an effectivedose of a neutral or a cationic polysaccharide compound in an admixturewith a dose of a compound to said subject in need thereof in order totreat fibrosis.

In another embodiment the above method is disclosed, wherein thefibrosis is of the liver. In yet another embodiment the method isdisclosed, wherein the fibrosis is of the lung. In another embodimentthe fibrosis is of the kidneys.

In another embodiment the polysaccharide compound is arhamnogalacturonan. In another embodiment the polysaccharide compound isan arabinogalactan. In another embodiment the galactomannan has amolecular weight between 20,000 and 400,000 D. In another embodiment theratio of mannose to galactose in a galactomannan is 1.7:1.

In another embodiment the ratio of mannose to galactose in agalactomannan is 2.2:1. In another embodiment a molecular weight of therhamnogalacturonan is between 20,000 and 400,000 D. In anotherembodiment the ratio of galactose to rhamnose in the rhamnogalactan is3.7:1. In another embodiment the ratio of galactose to rhamnose in therhamnogalactan is between 0.4 and 6.7 to 1. In another embodiment thearabinogalactan has a molecular weight between 20,000 and 200,000 D. Inanother embodiment the ratio of galactose to arabinose in thearabinogalactane is between 1.2 and 9.0 to 1.

In a further embodiment of the invention, galacto-rhamnogalacturonate(GR) is a branched heteropolymer of alternating 1,2-linked rhamnose and1,4-linked GalA residues that carries neutral side-chains ofpredominantly 1,4-b-D-galactose and/or 1,5-a-L-arabinose residuesattached to the rhamnose residues of the RGI backbone. GR side-chainsmay be decorated with arabinosyl residues (arabinogalactan I) or othersugars, including fucose, xylose, and mannose. These are also referredto in commercial use as pectic material.

In one embodiment, preparation involved modifying naturally occurringpolymers to reduce the molecular weight for the desired range, adjustingthe alkylated groups (demethoxylation or deacetylation), and adjustingside chain oligosaccharides for optimum efficacy. For example, naturalpolysaccharides may have a molecular weight range of between about40,000-1,000,000 with multiple branches of saccharides, for example,branches comprised of 1 to 20 monosaccharides of glucose, arabinose,galactose etc, and these branches may be connected to the backbone vianeutral monosaccharides such as rhamnose. These molecules may furtherinclude a single or chain of uronic acid saccharide backbone that may beesterified from as little as about 2% to as much as about 30%. Themultiple branches themselves may have multiple branches of saccharides,the multiple branches optionally including neutral saccharides andneutral saccharide derivatives creating mainly hydrophobic entities.

An example of a galactomannan is a polysaccharide prepared from guar gumand having a size is in the range of 2000-600,000 D or in the range of90,000 to 415,000 D or in the range of 20,000-200,000 D. In specificexamples, the galactomannan may have an average size molecular weight of50,000 D or 215,000 D. In a further embodiment of the invention, thegalactomannan is isolated from powder obtained from the seed of theplant Cyamopsis tetragonoloba.

In a further embodiment, a rhamnogalacturonate has a molecular weightrange of 2,000 to 200,000 D. In specific examples, therhamnogalacturonanate may have an average size molecular weight of34,000 D or 135,000 D and is obtained through chemical, enzymatic,physical treatments and purification from pectic substance of Citruspeels and apple pomace or soybean hull or alternatively processed fromsugar beet pectin.

In further embodiments of the invention, a galactomannan is used toreduce fibrosis under a antifibrotic action of an antifibrotic compoundwhen it is mixed with the compound prior to administration. Thegalactomannan may be a β-1,4 D-galactomannan. Moreover, thegalactomannan may include a ratio of 2.0-3.0 mannose to 0.5-1.5galactose. The ratio of mannose to galactose may be 2.6 mannose to 1.5galactose or 2.2 mannose to 0.9 galactose or 1.13 mannose to 1 galactoseor 2.2 mannose to 1 galactose.

In a further embodiment, the ratio of galacto-polysaccharide to anantifibrotic compound in the mixture may be in the range of 0.1:1 w/w to10:1 w/w. In an embodiment of the invention, administration of themixture results in a reduced fibrosis (as determined by a reduced levelof the specific markers) of greater than 20% compared to best standardof therapy. In another embodiment, the galacto-polysaccharide incombination with anti-fibrotic drugs reduced fibrosis by greater than50% compared with standard care.

A further embodiment of the invention provides a method for use intreating a fibrosis including but not limited to, of the liver, thelungs, the kidneys, the eye, the skin.

In one embodiment, an example of a polysaccharide includes:

Rhamnogalacturonate from Apple pulp

and Galactomannan from Guar gum

Galacto-Rhamnogalacturonate

In an embodiment of the invention, Galacto-rhamnogalacturonates (GR) isa branched heteropolymer of alternating a-1,2-linked rhamnose anda-1,4-linked GalA residues that carries neutral side-chains ofpredominantly 1,4-b-D-galactose and/or 1,5-a-L-arabinose residuesattached to the rhamnose residues of the RGI backbone. GR side-chainsmay be decorated with arabinosyl residues (arabinogalactan I) or othersugars, including fucose, xylose, and mannose. These are also referredto in commercial use as pectic material.

In one embodiment, soluble chemically alteredgalacto-rhamnogalacturonates are prepared by modifying naturallyoccurring polymers to reduce the molecular weight for the desired range,reducing the alkylated group (de-methoxylation or de-acetylation) Priorto chemical modification, the natural polysaccharides may have amolecular weight range of between about 40,000-1,000,000 with multiplebranches of saccharides, for example, branches comprised of 1 to 20monosaccharides of glucose, arabinose, galactose etc, and these branchesmay be connected to the backbone via neutral monosaccharides such asrhamnose. These molecules may further include a single or chain ofuronic acid saccharide backbone that may be esterified from as little asabout 2% to as much as about 30%. The multiple branches themselves mayhave multiple branches of saccharides, the multiple branches optionallyincluding neutral saccharides and neutral saccharide derivativescreating mainly hydrophobic entities.

We describe chemical modification procedures that involves a enzymatic,peroxide and transition metals or peroxide/ascorbate session of theglycosidic bond in the polymer backbone or alkaline reductivedepolymerization or controlled into smaller, branched polysaccharidemolecules, using controlled conditions of time, temperature and buffer.Treatments (see Example 1, 2, 3). The first purification procedure isextraction of the polysaccharide with alkaline and/or chelation solutionto remove proteins, pigments and other impurities.

The following are merely illustrative examples of the production ofpolysaccharides that are not meant to limit the invention.

Example 1 Method of Modifying Naturally Occurring Polysaccharides

A starting polysaccharide is treated with U.V. radiation or suspended in70% alcohol treatment for about 48 hours to reduce microbialcontamination. All further steps are conducted under semi-sterileconditions. After irradiation the polysaccharide is slowly dissolved indistilled water and the amount of total carbohydrate is determined bythe phenol sulfuric acid method (Fidler et al., Cirrhosis Res., (1973),vol. 41, pp. 3642-3956.)

A solution in distilled water is prepared at 20 g/L of polysaccharide,starting for example with USP pectin (Pelco) is made and pH is adjustedto pH 5.5 with 1 M sodium succinate, The polysaccharide solutions isthen incubated at fix temperature, for example; 20° C. and peroxideand/or ascorbate are added together as in example (FIG. 1) orsequentially.

H₂O₂ caused a slow scission of USP Pectin at pH 5.5, at 10 mM (FIG. 1).The half time required to double the specific fuidity was 15±72 h (FIG.1). L-Ascorbate at same condition and concentration induced fasterscission. By far the most dramatic effect, however, was produced bycombination of 5 mM ascorbate and 5 mM H₂O₂ which caused fasterscission. Sequential addition of ascorbate to polysaccharide solutionalready containing even 1 mM H₂O₂ caused further stimulation ofscission. The rate and extent of scission was determined by the dose ofascorbate added, time of addition post H₂O₂ addition, pH andtemperature. These indicate that an initial reaction preceded theScission process. A pH of 4.5, gave the shortest delay and the greatestrate of scission. Thus the enhanced effect of ascorbate depended on H₂O₂or dehydroascorbate produced by the reactions (below).

AH₂+O₂→A+H₂O₂

or

AH₂+H₂O₂→A+2H₂O

Where AH2 is ascorbate, and A is dehydroascorbate

For example digestion of 20 g/L of USP pectin with 10 mM H₂O₂ or 10 mMascorbate or the combination of both at 5 mM each indicate a linearrelation between digestion time and the viscometer measurements asbelow. The kinetics was also well correlated with incubationtemperature.

This method can be further enhanced in presence of metals like Ca⁺⁺,Cu⁺⁺ or Fe⁺⁺. The most likely source of cleavage is Fenton reaction(Halliwell, B. and Gutteridge, J. M. C. (1990) Methods Enzymol. 186,1-85) which generates ionized OH, requires H₂O₂ and the reduced form ofa transition metal ion, Cu+ reported being 60 times more effective thanFe2+.

All the polysaccharide samples usually contained measurable traces ofFe, Cu and Zn in ppm level. The Cu and Fe content was similar in severalcommercial polysaccharides (as reported in their C of A) and similarlyanalytical grade ascorbic acid contained low ppm traces of Cu and Fe.Therefore, when no transition metal are deliberately added, the Fentonreactions would be feasible.

Cu⁺+H₂O₂→OH+OH⁻+Cu²⁺  (3)

Example 2 Method of Modifying Naturally Occurring Polysaccharides

The pH of the polysaccharide solution is increased to pH 10 with, forexample, 3N NaOH. After short incubation at 5 to 50° C. for 30 to 60minutes, 10 to 20% ethanol is added and the purified polysaccharide isprecipitated. This removed proteins and pigments associated withcommercially available polysaccharides. The polysaccharide is thendissolved to a 20 g/L and then an acid is added, for exampletrifluoroacetic acid at final concentration of 0.01 to 1.0 M has beendemonstrated to give a controlled de-polymerization. Other acids orcombination of them like sulfuric, HCl, Acetate, propionic acid, ormethansulfonic acid can be used to shorten the hydrolysis time andimprove the yield of a desired structure of branched polysaccharidewithout oxidation. After appropriate time intervals, for example a timecourse from 10 minutes to 48 hours, at temperature of 15 to 121° C., thesolution is neutralized to pH 3 to 5, cooled to 4° C. and centrifuged toremove any insoluble matter. Then the supernatant is neutralized to afinal pH of about 6.0 to 8.0 with 1N NaOH for example, 20% ethanol isadded to recover the soluble polysaccharide. Ratio of polysaccharide toacid, type of acid, concentration, pH temperature and time interval areselected so to generate a soluble branched polysaccharide that has amolecular weight of 50 kD, 60, kD, 75 kD, 90 kD, 105 kD, 125 kD, 150 kD,175 kD, and up to 200 kD. The resulting soluble branched polysaccharideproduct can further washed with 70% ethanol or with 100% acetone toprovide a final dry powder. Thereupon the soluble branchedpolysaccharide is resolubilized in water to a final concentration ofabout 5-15% by weight for analytical identification, efficacy ortoxicological studies. The soluble branched polysaccharide may befurther diluted for use according to embodiments of the invention inwhich concentrations of 0.01-10% may be provided to cells. Depending onthe desired soluble branched polysaccharide composition and molecularweight.

Example 3 Method of Modifying Naturally Occurring Polysaccharides

The pH of the polysaccharide solution is increased to pH 9 with, forexample, 3N NaOH. After short incubation at 5 to 50 C for 30 to 60minutes, 10% ethanol is added and the purified polysaccharide isprecipitated. This removed proteins and pigments associated withcommercially available polysaccharides. Then reducing compound such as asodium borohydride, lithium borohydrate, sodium cyanoborohydride, sodiumtriacetoxyborohydride or other borohydrate salts to create a session byalkaline reductive mechanism of the glycosidic bonds. This formfragments of a size corresponding to a repeating subunit. (U.S. Pat. No.5,554,386). Again temperature and time can be used to shorten thehydrolysis time and improve the yield of polysaccharide. Afterappropriate time intervals, for example a time course from 30 minutes to24 hours, at temperature of 25 to 75° C., the solution is cooled to 4°C. and centrifuge to remove any insoluble matter. Then the supernatantis neutralized to a final pH of about 6.0 with 1N HCl for example, 20%ethanol is added to recover the soluble polysaccharide. Ratio ofpolysaccharide to reductive compound, type of compound, concentration,pH, temperature and time interval are selected so to generate a solublebranched polysaccharide that has a molecular weight of 50 kD, 60, kD, 75kD, 90 kD, 105 kD, 125 kD, 150 kD, 175 kD, and up to 200 kD. Theresulting soluble branched polysaccharide product can furtherfractionate with 20 to 70% ethanol and finally with 100% acetone toprovide a final dry powder. Thereupon the soluble branchedpolysaccharide is resolubilized in water to a final concentration ofabout 5-15% by weight for analytical identification, efficacy ortoxicological studies. The soluble branched polysaccharide may befurther diluted for use according to embodiments of the invention inwhich concentrations of 0.01-10% may be provided to cells. Depending onthe desired soluble branched polysaccharide composition and molecularweight.

The target molecular weight range for the chemically soluble branchedpolysaccharides is in the range of 50 to 200 kD.

As the temperature (or pH) increases, a so-called

-elimination starts. The

-elimination in present of alkaline borohydrates results in controlledprocess of chain cleavage accommodated with loss of viscosity andgelling properties, which are used to monitor the reaction

Example 4 Galactomannans

For example polysaccharide produced from Guar Gum a powder from seeds ofCyamopsis tetragonoloba

We provide a method of treating a subject with a antifibrotic compoundthat increases the efficacy of the antifibrotic compound. The methodrequires the co-administration of the compound with a polysaccharide. Inaddition to increasing efficacy, the co-administration of apolysaccharide with a antifibrotic compound may reduce the toxicity ofthe compound. In embodiments of the invention, the polysaccharide,galactomannan, has been shown to be effective in increasing the efficacyof antifibrotic compounds when coadministered with the compounds.Although the examples provided herein describe the beneficial effects ofgalactomannans, we do not exclude the possibility that otherpolysaccharides may have a similar effect. The increase in efficacy mayarise from a synergistic effect between the galactomannan and theantifibrotic compound mixture.

Both the polysaccharide and the antifibrotic compound may separately beformulated, in a dry form for example as a powder, or in a liquid form.In a preferred embodiment, the polysaccharide and antifibrotic compoundare mixed prior to administration. The mixture may be in the form of aliquid, a powder or an aerosol.

One of ordinary skill in the art can determine and prescribe theeffective amount of the antifibrotic composition required based onclinical protocols. In general, a suitable daily dose of a compositionof the invention will be that amount of the composition, which is thelowest dose effective to produce a antifibrotic effect.

Galactomannan is a polymer that may occur in a variety of size ranges.Moreover, the galactomannan may be derivatized or hydrolyzed to resultin fragments of the native molecule or may be reacted to providechemically modified forms of the native molecule. Embodiments of theinvention provide a galactomannan having a molecular weight in the rangeof 20,000-600,000 D. The galactomannan may further have a size in therange of 90-415,000 D or 40,000-200,000 D, or 50,000-80,000 D. Example 1utilizes a galactomannan with an average molecular weight of 65,000 Dwhile Example 2 utilizes a galactomannan with an average molecularweight of 83,000 D.

The ratio of mannose to galactose may vary according to the source ofthe galactomannan and the isolation procedure. In embodiments of theinvention, the galactomannan may have a mannose to galactose ratio of2.0-3.0, mannose: 0.5-1.5 galactose. The ratio of mannose to galactosemay be 2.6:1.5 or 2.2:0.9 or 1.13:1 or 2.2:1. In Example 1, the ratio ofmannose to galactose is 1.7:1 and in Example 2, the selected ratio ofmannose to galactose in the galactomannan is 2.2:1.

In one preferred embodiment, the structure of galactomannans is apoly-β-1,4-mannan backbone, with the side substituents bound viaα-1,6-glycoside linkages.

Example 5 Arabinogalactans

The active galacto-polysaccharide is produced from powder readilyavailable from the wood of the larch tree primarily Larix occidentalis(Western Larch). The process in general follow the preparation listedabove for rhamnogalacturonate and galactomannan. The target molecularweight is 20,000 to 70,000 D with at least 5% terminal galactose sidechain.

The following discussions and examples of assays utilized to demonstrateefficacy and effective dose are to be used as illustrative examples andare not meant to limit the present invention to the examplesillustrated.

Example 1 Liver, Lung, Kidney and Plasma Distribution of Radiolabeled(Tritiated) galactomannan in Healthy Male Athymic NCr-nu Mice

Twelve male NCr-nu athymic nude mice (Charles Rivers Laboratories,Raleigh, N.C.) were acclimated in the laboratory one week prior toexperimentation. The animals were housed in microisolator cages, fourper cage, and using a 12-hour light/dark cycle. All animals receivedsterilized tap water and sterile rodent food ad libitum. The animalswere observed daily and clinical signs were noted. The mice were healthyand had not been previously used in other experimental procedures. Themice were randomized and were comparable at the initiation of treatment.

Tritiation of the galactomannan was performed as follows. 12.8 mg of thegalactomannan was dissolved in 2.0 mL of water and exposed to 25 Curiesof tritium gas in the presence of Pd/BaSO₄ catalyst (120 mg, totallyinsoluble in water). After one hour the gas supply was removed, thecatalyst was filtered away, and the aqueous solution of thegalactomannan was evaporated to dryness repeatedly (four-fold, addingwater), until no labile tritium was found. Total yield of the labeledgalactomannan was 3.8 mC_(i), specific radioactivity was 300 μC_(i)/mg.

All twelve mice were given a single intravenous injection of cold ortritiated galactomannan (either 6 or 60 mg/kg) on the same day.Non-labeled galactomannan was formulated in saline, and tritiatedgalactomannan was added to the solution so that each animal received 10μC_(i) of radioactivity. All dosing solutions (100 μL each) were countedin duplicate. Six mice were injected with 6 mg/kg solution, and sixmice—with 60 mg/kg solution.

Two mice from each group were bled at 1, 6, and 24 hrs after injection,and plasma was prepared. Animals were then sacrificed; livers, kidneysand lungs were collected, weighed and flash-frozen for further analysis.

After weighing, livers were dissolved in 10 mL of Soluene 350 andincubated first for 4 hrs at 50° C., and at room temperature, untiltissues were solubilized. One mL of the resulting solution was countedin a scintillation counter as a single sample. Based on tissue weightand the sample volume, the number of μC_(i) of tritiated galactomannanper gram of tissue was calculated.

Kidneys were treated in the same manner, but dissolved in two mL ofSoluene. After the tissue was solubilized at room temperature, 15 mL ofSafety Solve scintillation fluid was added and samples were incubatedovernight. Five mL of the resulting solution were diluted in 15 mL ofSafety Solve and counted in a scintillation counter as a single sample.Lungs were treated in the same manner but dissolved in one mL ofSoluene. Plasma samples (50 μL each) were placed direct into SafetySolve and counted as a single sample.

The data are shown in Table 1.

TABLE 1 Distribution of radiolabeled galactomannan (at 6 or 60 mg/kg) intissues of mice 1 hr after 6 hr after 24 hrs after injection injectioninjection Liver μC_(i) of ³H-galactomannan 0.262 0.196 0.169 per liver,total Same, per 1 g of liver 0.219 0.146 0.129 Plasma μC_(i) of³H-galactomannan 0.201 0.095 0.106 per mL of plasma Kidney μC_(i) of³H-galactomannan 0.120 0.060 0.040 per kidney, total Same, per 1 g ofkidney 0.302 0.131 0.087 Lungs μC_(i) of ³H-galactomannan 0.019 0.0120.011 per lungs, total Same, per 1 g of lungs 0.117 0.063 0.060

The statistical evaluation was based on experiments to trace andquantify the labeled galactomannan in organs/tissues (liver, kidneys,lung, and plasma). Six mice were treated with galactomannan at 60 mg/kgwith each of 2 mice sacrificed at 1, 6, and 24 hours; six mice weretreated with galactomannan at 6 mg/kg with each of 2 mice sacrificed at1, 6, and 24 hours, as described above. The percentages of³H-galactomannan recovered per organ (μC_(i)/gram) was used foranalyses; plasma outcome (μC_(i)/ml) was counted from the entire sample.

The assessment of radiolabel uptake was challenging with only two miceper treatment-sacrifice time combination and occasional outliers. Toaddress the number of mice per group, pooling tests were performed forthe two galactomannan treatment groups; this would potentially increasesample size per group to four. To address possible outliers, alloutcomes for each individual mouse was visually compared to the othermice in the series-treatment-time combination; the four possible miceoutcomes were considered in this evaluation since any sigma-based rulewould have excluded none or both observations if applied separately tothe two different series.

SAS (Version 6.12, Cary, N.C.) was used for all analyses. PROC ANOVA wasused for pooling tests, while PROC FREQ was used to estimate means andstandard deviations.

It was observed that galactomannan freely binds to liver, kidney, lung,and plasma, and did not reach limits of the binding, e.g. did not reachsaturation of the binding between the 6 mg/kg and 60 mg/kg doses. When 6mg/kg (with a relative radioactivity of 1.0) and 60 mg/kg (with arelative radioactivity of 0.1) doses of galactomannan were administered,the amount of bound radioactive galactomannan was the same; that is, theamount of bound galactomannan increased 10-fold for the 10-times higherdose.

The distribution of radioactivity in whole tissues as well as per weightor volume (in plasma) was practically identical for 6 and 60 mg/kg ofgalactomannan, hence, the respective data were pooled for Table 1.Overall, the data in Table 1 are average for four animals.

³H-galactomannan elimination from plasma, kidneys, and lungs in thevarious groups was relatively slow. An average of approximately 50% ofthe one-hour radioactivity was detected at 6 hours. Elimination of³H-galactomannan from the liver was more gradual than in other tissues,and on average, more than 50% of the radioactivity detected at one hourafter injection was still present at 24 hours. This can be compared, forexample, with clearance of 5-fluorouracil from the liver, which waseliminated to 1.6% after 24 hrs, and from the lungs and the kidneys,which was eliminated to 3.6% and 3.8%, respectively, for the sameperiod.

Example 2 Assessing the Antifibrotic Efficacy of a ModifiedGalacto-Rhamnogalacturonate Compounds in LX2, an Immortalized HumanHepatic Stellate Cell Line

The antifibrotic activity of a galacto-polysaccharides was determined intriplicate, at five concentrations and three time points (4, 12 and 24hrs) on hepatic stellate cell (HSC) proliferation, employing the methodof 3H-Thymidine incorporation, as well as regarding thegalacto-polysaccharide effect on the following markers of fibrogenesis:

-   -   Collagen I (a marker on fibrosis)    -   Alpha 1-smooth muscle actin (a marker on activation of stellate        cells)    -   Beta PDGF-receptor (a marker on proliferation)    -   MMP2, MMP9, TIMP1 and TIMP2 (markers on matrix degradation)    -   TFG-β1 (a marker on fibrogenesis).

Two more polysaccharides served as reference compounds. They were agalacto-rhamnogalacturonate from citrus, and a galactomannan from guargum.

LX2 cells, an immortalized human hepatic stellate cell line, wereincubated at 37° C. in an atmosphere of 5% CO₂ in Dulbecco's modifiedminimal essential medium (Gibco BRL Life Technologies, Rockville, Md.)containing 1% fetal calf serum (FCS), 2 mmol/L of L-glutamine and 5000IU/mL of penicillin/5000 g/mL streptomycin for 1 to 2 days beforestarting experiments. They were then serum starved with 0.1% BSA (0.2%FCS) for 24 hours, and treated with each of the three polysaccharides inthe following concentrations: galactomannan 0.5-1 mg/ml, citrusgalacto-rhamnogalacturonate 0.1-0.5 mg/ml or applegalacto-rhamnogalacturonate 0.1-0.5 mg/ml for 12, 24, 48 and 72 hours.The exact concentrations of each modified polysaccharide was adjustedaccording to ongoing data during the experiment.

To confirm that the hypothesized reductions in fibrogenic markers werenot accounted for by decreasing cell viability, an MTT viability assaywas performed. 200 μl of the MTT solution (2 mg of MTT in 1 ml of DMEM)weree added to each well of 24-well plate and incubated at 37° C. for 1hr. After the incubation, the media was discarded and 100 μl ofN-propanol added to each well. After 5-10 minutes of reaction, 50 μl ofthe solution was taken from each well and transferred into 96-well plateand the O.D. was read with ELISA Reader at 570 nm.

To indicate that the effects of the polysaccharides were specific forfibrogenic gene expression, cell proliferation was assessed in thepresence of the polysaccharides. Assessment of proliferation is avaluable indicator of stellate cell activation, and thus compounds thatreduce proliferation are expected to reduce the overall number offibrogenic cells during liver injury, which might be erroneously takenas a specific marker-reducing effect.

Cells were serum starved, then incubated in medium containing 3Hthymidine as previously described (22). After washing the cells withcold PBS 3 times, 500 μl of 0.25 N NaOH/0.25% SDS is added to each wellof 24-well plate and transferred to Scintillation vials containing 100μl of 1N HCl. Then 5 ml of Scintillation Solution is then added to thevial and vortexed. CPM is read in Scintillation Counter (LS3801 LiquidScintillation System, BECKMAN).

The antifibrogenic activity of the polysaccharides was measured by theireffect on expression of established fibrotic markers by Quantitativereal time RT-PCR of fibrotic marker mRNAs. RNA from LX2 cells wasextracted and purified using the Qiagen RNAeasy mini-kit. Concentrationswas then measured in Life Science UV/VIS spectrophotometer DU 530Bekman. Total RNA was reverse transcribed to complementary DNA (cDNA)using the Reverse Transcription System by Promega (Madison, Wis.)(Sprint™ PowerScript™ Double PrePrimed Single Shots, Clontech, USA). Onemicrogram of RNA in 7.7 μl of nuclease-free water was added to 2.5 μl of10× reverse transcriptase buffer, 10 μl of 25 mM MgCl₂, 2.5 μl of 10 mMdNTP, 1 μl of random primer, 0.5 μl of RNase inhibitor and 0.8 μl of AMVreverse transcriptase (one microgram of RNA was added into a tubecontaining reaction mixture which contains 0.5 μg of PowerScript ReverseTranscriptase, 20 μM Random hexamer primers, 20 μM Oligo(dT) 18 primers,10 mg/ml BSA, 1M DTT, 10 mM dNTP mix, 10× reaction buffer,cryoprotectant and stabilizers). The reaction was performed for 10 minat 25° C. (annealing), 60 min at 42° C. (cDNA-synthesis), and 5 min at95° C. (enzyme denaturation), 80 min at 42° C., 10 min at 70° C. byPTC-200, Peltier Thermal Cycler.

Real-time quantitative PCR was analyzed in triplicate and performed withABI Prism 7900HT Sequence Detection System (Applied Biosystems, FosterCity, Calif.) LightCyclerR480, Roche, USA. One microliter of cDNA wasused in each PCR reaction, Platinum Taq DNA polymerase, Syber green, 100mM dNTP (Invitrogen Corp, Carlsbad, Calif.) Taq Polymerase, dNTP, DMSO,25 nM MgCl₂, 10×Taq Buffer, NF H2O, Zybo Green, and the fluorescencesignals was captured during each of the 40(45) cycles, in proportion tothe quantities of double-stranded DNA (denaturation 15 s at 95° C.,annealing 15 s at 56° C. and extension 40 s at 72° C.) (1 cycle fordenaturation 5 min at 95° C.), 45 cycles for amplification (10 sec at95° C., 10 sec at 55° C., 12 sec at 72° C.), 12 sec at 65° C. forMelting Curve, and 10 sec at 40° C. for Cooling). Detection of the PCRproducts by agarose gel electrophoresis was used to confirm thehomogeneity of the DNA products. GAPDH was used as a reference gene fornormalization, and water was be used as negative control.

Relative quantitation was calculated using the comparative thresholdcycle (CT) method as described in the User Bulletin, ABI PRISM 7900HTSequence Detection System (Relative quantification analyses was doneusing the LightCycler 480 Relative Quantification Software supplied bythe company). CT indicates the fractional cycle number at which theamount of amplified target genes reaches a fixed threshold within thelinear phase of gene amplification, and is inversely related to theabundance of mRNA transcripts in the initial sample. Mean CT ofduplicate (triplicate) measurements were used to calculate ΔCT as thedifference in CT for target and reference (GAPDH) genes. ΔCT for eachsample was compared to the corresponding CT of the control experimentand expressed as ΔΔCT. Relative quantization was expressed asfold-induction or repression of the gene of interest compared to thecontrol condition according to the formula 2-ΔΔCT.

A figure below (FIG. 2) shows that the galacto-rhamnogalacturonate(GR-300) suppresses the fibrosis markers' expression between 50% and 80%while the galactomannan (DAVANAT) and the galacto-rhamnogalacturonate(GR-200) decrease fibrosis markers' expression from 0 to 40%. Theseresults indicate a significant antifibrotic effect of thepolysaccharides, particularly that of apple origin, on human hepaticstellate cells, and suggest that the polysaccharides can protect fromand even reverse the progression of liver fibrosis.

The results (FIG. 2) of qRT-PCR tests for fibrosis markers Collagen I(COLL 1), alpha-1 smooth muscle actin (ASMA), platelet derived growthfactor receptor-beta (PDGFBR), transforming growth factor receptorbeta-1 (TGFBR1), matrix metalloproteinase 2 (MMP2), tissue inhibitor ofmetalloproteinase 1 (TIMP I) and tissue inhibitor of metalloproteinase 2(TIMP II) after 48 hrs as control, and in the presence of 1 mg/mlDavanat, 0.1 mg/ml GR-200 or 0.1 mg/ml GR-300. The results are shownafter normalization to GAPDH expression levels as a house keeping gene.

In order to confirm that the observed reductions in fibrogenic markersare not accounted for by decreasing cell viability, an initial MTT cellviability assay was performed on the LX2 cell line assayed in the aboveFigure. The rationale behind assessing viability is to demonstrate thatthe compounds are not simply toxic in a non-specific manner, but ratherthat they exerted quantitative, measurable effects on the biology ofhepatic stellate cells through specific molecular interactions.

Obtained results showed that the significantly decreased expression offibrosis markers was not due to decreased cell viability (FIG. 3) butrather due to an actual effect on mRNA expression. This Figure showsresults of the MTT viability test for human hepatic stellate cell (HSC)line LX2 in the absence of polysaccharides as control, and in thepresence of Davanat (1 mg/ml), GR-200 and GR-300 (0.1 mg/ml) (bar on theright). The data show that none of the three polysaccharidessignificantly effects the cell viability within error margin (typically2% to 10% in these experiments).

Similarly, there was no significant effect of any of the threepolysaccharides on cell LX2 proliferation, measured using ³H-Thymidineincorporation assay (Figure below).

The results (FIG. 4) shows human hepatic stellate cell (HSC) line LX2proliferation test using 3H-Thymidine incorporation assay in the absenceof polysaccharides as control, and in the presence of 1 mg/ml DAVANAT,GR-200 or GR-300. The data show that none of the three polysaccharidessignificantly effects the cell proliferation within error margin(typically 10% to 30% in these experiments)

One can see that the galacto-rhamnogalacturonate from apple showeddownregulation of a full panel of activation-related mRNAs, indicating aglobal effect on slowing down stellate cell specific activation. This isa manifestation of fibrotic process slowing down or even reversing.

Example 3 In-Vivo Studies of the Admixture of the Present Invention inModel Animals

Pathogen-free male Wistar rats were housed at a constant temperature andsupplied with laboratory chow and water ad libitum. Thioacetamide (TAA,from Wako Pure Chemical Co., Osaka, Japan) was used to induce LiverFibrosis Model. The induction regimen and dosage was 50 mg/body,intraperitoneally administrated twice a week into rats (n=8-15) for upto 8 weeks. The admixture was administered either intraperitoneally ororally every day for 6 weeks. For testing reversibility of disease theadmixture was administered either intraperitoneally or orally during thelast 3-4 weeks of the induction period. 24-48 after the final treatment,the animals were anesthetized, and the peritoneal cavity was opened. Theliver was perfused with phosphate-buffered saline via the portal toremove all blood from the whole liver lobules. Subsequently, part of theliver was treated with 10% formaldehyde and used for histologicexamination. The remaining part was frozen in liquid nitrogen and storedat 80° C. for fibrosis markers analysis.

In other animal model fibrosis and cirrhosis were induced by Bile DuctLigation. Rats were laparotomized and the common bile ducts were ligatedat two different sites.

The rats were administered with the admixture—in this example includingcorticosteroid (10 mg/body)—intraperitoneally every day for 2 weeks. Theresults were that treatment with the admixture either intraperitoneallyor orally suppressed fibrosis of the liver by at least 50% versuscontrol untreated animals.

What is claimed is:
 1. A composition comprising an effective amount of amodified galacto-rhamnogalacturonan compound and an acceptablepharmaceutical carrier, wherein the modified galacto-rhamnogalacturonancompound is a branched heteropolymer having a backbone of alternatingα-1,2 linked rhamnose and α-1,4-linked GalA residues that carriesneutral side-chains of predominantly 1,4-β-D-galactose and/or1,5-α-L-arabinose residues attached to the rhamnose residues of thebackbone, and wherein the galacto-rhamnogalacturonan compound ismodified by demethoxylation, deacetylation or depolymerization; whereinthe effective amount of the modified galacto-rhamnogalacturonan, whenadministered in a subject having at least one of the following: chronickidney disease associated with the development of fibrosis, establishedkidney fibrosis, or cirrhosis, is capable of inhibiting or slowing downof the progression of kidney fibrosis or cirrhosis or reduction ofestablished kidney fibrosis or cirrhosis; wherein the modifiedgalacto-rhamnogalacturonan compound wherein, when thegalacto-rhamnogalacturonan compound is utilized to treat LX2immortalized human hepatic stellate cells in a MTT cell viability assay,the assay treatment results in substantially no decreased viability ofactivated hepatic stellate cells following administration of thecompound.
 2. The composition of claim 1 wherein the modifiedgalacto-rhamnogalacturonan compound is derived from citrus pectin, applepectin, soybean hull pectin or sugar beet pectin.
 3. The composition ofclaim 1 wherein the modified galacto-rhamnogalacturonan compound isderived from USP pectin.
 4. The composition of claim 1 wherein themodified galacto-rhamnogalacturonan compound has a molecular weightbetween 20 kDa and 400 kDa.
 5. The composition of claim 1 wherein themodified galacto-rhamnogalacturonan compound has a molecular weightbetween 2 kDa and 200 kDa.
 6. The composition of claim 1 wherein theratio of galactose to rhamnose in the modifiedgalacto-rhamnogalacturonan is 3.7 to 1
 7. The composition of claim 1wherein the ratio of galactose to rhamnose in the modifiedgalacto-rhamnogalacturonan is between 0.4 to 1 and 6.7 to
 1. 8. Thecomposition of claim 1 wherein the modified galacto-rhamnogalacturonanfurther comprises fucose, xylose, mannose or combinations thereof. 9.The composition of claim 1 further comprising an antifibrotic compound.10. A composition comprising an effective amount of a modifiedgalacto-rhamnogalacturonan compound and an acceptable pharmaceuticalcarrier, wherein the modified galacto-rhamnogalacturonan compound is abranched heteropolymer having a backbone of alternating α-1,2 linkedrhamnose and α-1,4-linked GalA residues that carries neutral side-chainsof predominantly 1,4-β-D-galactose and/or 1,5-α-L-arabinose residuesattached to the rhamnose residues of the backbone, and wherein thegalacto-rhamnogalacturonan compound is modified by demethoxylation,deacetylation or depolymerization; wherein the effective amount of themodified galacto-rhamnogalacturonan, when administered in a subjecthaving at least one of the following: chronic lung disease associatedwith the development of fibrosis, established lung fibrosis, orcirrhosis, is capable of inhibiting or slowing down of the progressionof lung fibrosis or cirrhosis or reduction of established lung fibrosisor cirrhosis; wherein the modified galacto-rhamnogalacturonan compoundwherein, when the galacto-rhamnogalacturonan compound is utilized totreat LX2 immortalized human hepatic stellate cells in a MTT cellviability assay, the assay treatment results in substantially nodecreased viability of activated hepatic stellate cells followingadministration of the compound.
 11. A method comprising the steps of:Obtaining a modified galacto-rhamnogalacturonan compound; Wherein themodified galacto-rhamnogalacturonan compound is a branched heteropolymerhaving a backbone of alternating α-1,2 linked rhamnose and α-1,4-linkedGalA residues that carries neutral side-chains of predominantly1,4-β-D-galactose and/or 1,5-α-L-arabinose residues attached to therhamnose residues of the backbone and wherein thegalacto-rhamnogalacturonan compound is modified by demethoxylation,deacetylation or depolymerization; and Administering parenterally to asubject having at least one of the following disease: chronic kidneydisease associated with the development of fibrosis, established kidneyfibrosis or cirrhosis, chronic lung disease associated with thedevelopment of fibrosis, established lung fibrosis or cirrhosis, aneffective dose of the galacto-rhamnogalacturonan compound in anacceptable pharmaceutical carrier that results in at least one of thefollowing: Inhibition or slowing down of the progression of the fibrosisor cirrhosis or reduction of established fibrosis or cirrhosis; orreduction in the medical consequences of fibrosis or cirrhosis; wherein,when the galacto-rhamnogalacturonan compound for parenteraladministration is utilized to treat LX2 immortalized human hepaticstellate cells in a MTT cell viability assay, the assay treatmentresults in substantially no decreased viability of activated hepaticstellate cells following administration of the compound.
 12. The methodof claim 11 wherein in the step of obtaining the modifiedgalacto-rhamnogalacturonan compound is obtained from USP pectin.
 13. Themethod of claim 11 wherein in the step of obtaining the modifiedgalacto-rhamnogalacturonan compound is obtained from citrus pectin,apple pectin, soybean hull pectin or sugar beet pectin.
 14. The methodof claim 11 wherein in the step of obtaining the modifiedgalacto-rhamnogalacturonan compound has a molecular weight between 20kDa and 400 kDa.
 15. The method of claim 11 wherein in the step ofobtaining the modified galacto-rhamnogalacturonan compound has amolecular weight between 2 kDa and 200 kDa.
 16. The method of claim 11wherein in the step of obtaining the ratio of galactose to rhamnose inthe modified galacto-rhamnogalacturonan is 3.7 to
 1. 17. The method ofclaim 11 wherein in the step of obtaining the ratio of galactose torhamnose in the modified galacto-rhamnogalacturonan is between 0.4 to 1and 6.7 to
 1. 18. The method of claim 11 wherein in the step ofobtaining the modified galacto-rhamnogalacturonan further comprisesfucose, xylose, mannose or combinations thereof.
 19. The method of claim11 wherein in the step of administering the modifiedgalacto-rhamnogalacturonan is in an admixture with a therapeutic agent.20. The method of claim 19 wherein the therapeutic agent is anantifibrotic compound.